RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
NewGLab Pharma Co Stock

NewGLab Pharma Co ROA 2024

NewGLab Pharma Co ROA

0.07

Ticker

214870.KQ

ISIN

KR7214870008

In 2024, NewGLab Pharma Co's return on assets (ROA) was 0.07, a -102.84% increase from the -2.32 ROA in the previous year.

NewGLab Pharma Co Aktienanalyse

What does NewGLab Pharma Co do?

NewGLab Pharma Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding NewGLab Pharma Co's Return on Assets (ROA)

NewGLab Pharma Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing NewGLab Pharma Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider NewGLab Pharma Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in NewGLab Pharma Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about NewGLab Pharma Co stock

What is the Return on Assets (ROA) of NewGLab Pharma Co this year?

The Return on Assets (ROA) of NewGLab Pharma Co is 0.07 undefined this year.

What was the ROA of NewGLab Pharma Co compared to the previous year?

The ROA of NewGLab Pharma Co has increased by -102.84% compared to the previous year.

What consequences do high ROA have for investors of NewGLab Pharma Co?

A high ROA is advantageous for investors of NewGLab Pharma Co, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in NewGLab Pharma Co?

A low ROA can be unfavorable for investors of NewGLab Pharma Co as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of NewGLab Pharma Co affect the company?

An increase in ROA of NewGLab Pharma Co can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of NewGLab Pharma Co impact the company?

A reduction in the ROA of NewGLab Pharma Co can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of NewGLab Pharma Co?

Some factors that can influence the ROA of NewGLab Pharma Co include revenue, operating costs, asset structure, and industry average.

Why is the ROA of NewGLab Pharma Co important for investors?

The ROA of NewGLab Pharma Co is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can NewGLab Pharma Co take to improve ROA?

To improve ROA, NewGLab Pharma Co can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does NewGLab Pharma Co pay?

Over the past 12 months, NewGLab Pharma Co paid a dividend of 25 KRW . This corresponds to a dividend yield of about 0.36 %. For the coming 12 months, NewGLab Pharma Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of NewGLab Pharma Co?

The current dividend yield of NewGLab Pharma Co is 0.36 %.

When does NewGLab Pharma Co pay dividends?

NewGLab Pharma Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of NewGLab Pharma Co?

NewGLab Pharma Co paid dividends every year for the past 0 years.

What is the dividend of NewGLab Pharma Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is NewGLab Pharma Co located?

NewGLab Pharma Co is assigned to the 'Information technology' sector.

Wann musste ich die Aktien von NewGLab Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of NewGLab Pharma Co from 4/20/2016 amounting to 50 KRW, you needed to have the stock in your portfolio before the ex-date on 12/29/2015.

When did NewGLab Pharma Co pay the last dividend?

The last dividend was paid out on 4/20/2016.

What was the dividend of NewGLab Pharma Co in the year 2023?

In the year 2023, NewGLab Pharma Co distributed 0 KRW as dividends.

In which currency does NewGLab Pharma Co pay out the dividend?

The dividends of NewGLab Pharma Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von NewGLab Pharma Co

Our stock analysis for NewGLab Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NewGLab Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.